Tolevamer, an orally administered, toxin-binding polymer for Clostridium difficile-associated diarrhea.

Journal Article (Journal Article;Review)

Genzyme Corp is developing tolevamer, an anionic toxin-binding polymer that binds and neutralizes the Clostridium difficile A and B toxins, for the potential treatment of C difficile-associated diarrhea (CDAD). Two phase III clinical trials of tolevamer in patients with CDAD have been completed and results from the second trial are expected to be released imminently.

Full Text

Duke Authors

Cited Authors

  • Scheinfeld, N; Biggers, K

Published Date

  • August 2008

Published In

Volume / Issue

  • 9 / 8

Start / End Page

  • 913 - 924

PubMed ID

  • 18666039

International Standard Serial Number (ISSN)

  • 1472-4472

Language

  • eng

Conference Location

  • England